2020

1. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

   The Lancet Respiratory Medicine, Vol. 8, Núm. 11, pp. 1132-1143